F. Boyle

625 total citations
13 papers, 430 citations indexed

About

F. Boyle is a scholar working on Oncology, Cancer Research and General Health Professions. According to data from OpenAlex, F. Boyle has authored 13 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 4 papers in Cancer Research and 3 papers in General Health Professions. Recurrent topics in F. Boyle's work include Breast Cancer Treatment Studies (4 papers), Cancer survivorship and care (3 papers) and Patient-Provider Communication in Healthcare (3 papers). F. Boyle is often cited by papers focused on Breast Cancer Treatment Studies (4 papers), Cancer survivorship and care (3 papers) and Patient-Provider Communication in Healthcare (3 papers). F. Boyle collaborates with scholars based in Australia, United Kingdom and India. F. Boyle's co-authors include Phyllis Butow, Martin H.N. Tattersall, Jane Beith, Rhonda Brown, Richard Brown, Michael Friedländer, Nicholas Wilcken, Alan S. Coates, Martin R. Stockler and R. J. Simes and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Breast Cancer Research and Treatment.

In The Last Decade

F. Boyle

11 papers receiving 416 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. Boyle Australia	9	198	181	134	81	71	13	430
Melissa Figueiredo United States	9	301 1.5×	174 1.0×	133 1.0×	68 0.8×	170 2.4×	9	540
Melanie Brooke United Kingdom	7	284 1.4×	123 0.7×	120 0.9×	129 1.6×	111 1.6×	13	492
Michelle Tallarico United States	9	195 1.0×	67 0.4×	96 0.7×	42 0.5×	49 0.7×	9	391
Reneé Royak-Schaler United States	14	298 1.5×	140 0.8×	123 0.9×	47 0.6×	81 1.1×	23	559
Kim Sprunck‐Harrild United States	13	176 0.9×	111 0.6×	126 0.9×	129 1.6×	115 1.6×	25	441
Davinia Seah Australia	12	245 1.2×	52 0.3×	135 1.0×	80 1.0×	48 0.7×	24	473
Jennifer Wiernikowski Canada	9	425 2.1×	141 0.8×	238 1.8×	159 2.0×	126 1.8×	11	631
Worta J. McCaskill-Stevens United States	7	168 0.8×	140 0.8×	206 1.5×	37 0.5×	33 0.5×	18	470
Faustine Williams United States	12	247 1.2×	81 0.4×	67 0.5×	41 0.5×	69 1.0×	62	492
Neil Love United States	9	353 1.8×	78 0.4×	78 0.6×	109 1.3×	146 2.1×	26	518

Countries citing papers authored by F. Boyle

Since Specialization

Citations

This map shows the geographic impact of F. Boyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Boyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Boyle more than expected).

Fields of papers citing papers by F. Boyle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Boyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Boyle. The network helps show where F. Boyle may publish in the future.

Co-authorship network of co-authors of F. Boyle

This figure shows the co-authorship network connecting the top 25 collaborators of F. Boyle. A scholar is included among the top collaborators of F. Boyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Boyle. F. Boyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Murray, N., Prudence A. Francis, Nicholas Zdenkowski, et al.. (2022). 91MO Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials Group ANZ 1401 ELIMINATE trial. Annals of Oncology. 33. S164–S165. 2 indexed citations

Cameron, Barbara, Kate Webber, Hongshou Li, et al.. (2020). Genetic associations of fatigue and other symptoms following breast cancer treatment: A prospective study. Brain Behavior & Immunity - Health. 10. 100189–100189. 11 indexed citations

Smith, Kortnye, Julie Winstanley, F. Boyle, et al.. (2017). Madarosis: a qualitative study to assess perceptions and experience of Australian patients with early breast cancer treated with taxane-based chemotherapy. Supportive Care in Cancer. 26(2). 483–489. 11 indexed citations

Hammarberg, Karin, Elizabeth Sullivan, Lesley Halliday, et al.. (2017). Health care experiences among women diagnosed with gestational breast cancer. European Journal of Cancer Care. 27(2). e12682–e12682. 21 indexed citations

Thewes, Belinda, Melanie L. Bell, Phyllis Butow, et al.. (2013). Psychological morbidity and stress but not social factors influence level of fear of cancer recurrence in young women with early breast cancer: results of a cross‐sectional study. Psycho-Oncology. 22(12). 2797–2806. 73 indexed citations

Cameron, Barbara, Barbara Bennett, Hongshou Li, et al.. (2012). Post-cancer fatigue is not associated with immune activation or altered cytokine production. Annals of Oncology. 23(11). 2890–2895. 16 indexed citations

Lee, Chee Khoon, Harold Hudson, Martin R. Stockler, et al.. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment. 129(2). 467–476. 10 indexed citations

Brown, Richard, Phyllis Butow, F. Boyle, & Martin H.N. Tattersall. (2006). Seeking informed consent to cancer clinical trials; evaluating the efficacy of doctor communication skills training. Psycho-Oncology. 16(6). 507–516. 77 indexed citations

Duric, V., Martin R. Stockler, Stéphane Héritier, et al.. (2005). Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?. Annals of Oncology. 16(11). 1786–1794. 100 indexed citations

10.

Duric, V., Martin R. Stockler, PN Butow, et al.. (2005). Comparing patients’ and their partners’ preferences for adjuvant chemotherapy (ACT) in early breast cancer (EBC). Journal of Clinical Oncology. 23(16_suppl). 6074–6074. 2 indexed citations

11.

Duric, V., Martin R. Stockler, PN Butow, et al.. (2004). Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC). Journal of Clinical Oncology. 22(14_suppl). 787–787.

12.

Duric, V., Martin R. Stockler, Phyllis Butow, et al.. (2004). Predictors of the benefits women consider necessary to make adjuvant chemotherapy (ACT) worthwhile for early breast cancer (EBC). Journal of Clinical Oncology. 22(14_suppl). 787–787.

13.

Butow, Phyllis, et al.. (2002). Lay constructions of decision‐making in cancer. Psycho-Oncology. 11(4). 295–306. 107 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact